Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies

Cancer in the Midst of COVID-19, A Report

COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular Therapy

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study - eClinicalMedicine

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study - eClinicalMedicine

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies

Frontiers SARS-CoV-2 Variants, Vaccines, and Host Immunity

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study - The Lancet Haematology

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine

Vaccines, Free Full-Text

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis